Key Takeaway: Septerna has reported progress in its business operations, particularly highlighting the ongoing Phase 1 clinical trial for SEP-479, an oral small molecule PTH1R agonist. The trial's pharmacokinetic profile indicates that once-daily dosing is feasible. Additionally, the company's robust cash position of $516.5 million is expected to sustain its operational plans through at least 2029.
Market Sentiment Analysis
POSITIVE FACTORS
Ongoing Phase 1 clinical trial for SEP-479 shows promise.
Cash position of $516.5 million ensures operational stability.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Cash runway
~58 mo
Minimal dilution risk
Lead asset
SEP-631
Phase 1 · Healthy Volunteers
Full Press Release Details
Phase 1 Clinical Trial Ongoing for SEP-479, an Oral Small Molecule PTH1R Agonist SEP-479 Observed Clinical Pharmacokinetic Profile Supports Once-Daily Dosing; SAD / MAD Data Expected in Q1 2027 Cash Position of $516.5 Million Expected to Support Operating Plans at Least into 2029 SOUTH SAN
Frequently Asked Questions
What is SEP-479?
SEP-479 is an oral small molecule PTH1R agonist currently in Phase 1 clinical trials.
What are the dosing expectations for SEP-479?
The clinical pharmacokinetic profile of SEP-479 supports once-daily dosing.
When will data from the SEP-479 trial be available?
SAD and MAD data for SEP-479 are expected in Q1 2027.
What is Septerna's cash position?
Septerna has a cash position of $516.5 million, supporting operations until at least 2029.